Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Despite missing the primary endpoint, the novel K V 7 potassium channel opener azetukalner showed benefit in major depressive ...

The novel PDE10A inhibitor CPL'36 offers a new mechanism of action and is both safe and effective for acute exacerbations of schizophrenia, new research suggests.